Timothy C. Barabe, a director of Heartflow Inc., acquired 5,000 shares of common stock on July 17, 2026, at a price of $19 per share, according to a beneficial ownership update filed with the Securities and Exchange Commission. The transaction brings Barabe's direct beneficial ownership of Heartflow common stock to 184,521 shares. Barabe also received 5,000 fully exercisable stock options with a strike price of $19 and an expiration date of August 7, 2035, increasing his derivative securities position to 18,710 options. The disclosure provides investors with insight into insider trading activity at the cardiac imaging technology company.

Key Points

  • NASDAQ: HTFL
  • Director Timothy C. Barabe purchased 5,000 shares of common stock at $19 per share on July 17, 2026
  • Barabe's total direct common stock ownership increased to 184,521 shares following the transaction
  • Barabe received 5,000 stock options with a $19 exercise price, expiring August 7, 2035, increasing his total derivative position to 18,710 options

Details of the Common Stock Acquisition

Timothy C. Barabe, identified as a director of Heartflow Inc., engaged in an open market purchase of 5,000 shares of the company's common stock on July 17, 2026. The transaction was executed at $19 per share, representing a total acquisition value of $95,000. This purchase was reported through a Form 4 statement filed on July 20, 2026, which tracks changes in beneficial ownership by company insiders subject to Section 16 reporting obligations. The shares were acquired directly by Barabe and are held in his personal name rather than through an intermediary or trust arrangement.

Following completion of this transaction, Barabe's total direct beneficial ownership of Heartflow common stock reached 184,521 shares. The significant size of his holdings indicates a substantial stake in the cardiac imaging diagnostics firm. The disclosure documents show the transaction code as "M," which typically denotes a non-open market or private acquisition, though the filing indicates this was an open market purchase. Investors monitoring insider activity at Heartflow may view director stock purchases as a signal of confidence in the company's business prospects and valuation at the transaction price.

Stock Option Grant and Derivative Securities Position

In addition to the common stock purchase, Barabe received a grant of 5,000 stock options on the same transaction date of July 17, 2026. These options carry a strike price of $19 per share, which matches the price at which Barabe purchased the common shares on that date. The options are fully exercisable immediately and expire on August 7, 2035, providing a nine-year window for potential exercise. This grant structure aligns the director's equity incentives with the company's long-term performance and share price appreciation prospects.

The option grant increased Barabe's total beneficial ownership of derivative securities to 18,710 options. The reporting shows these derivative securities are held directly by Barabe rather than through an indirect ownership structure. The grant of options alongside the common stock purchase may reflect Heartflow's compensation strategy for retaining board-level leadership and incentivizing alignment between director interests and shareholder value creation. The nine-year expiration window provides substantial time for the options to move in or out of the money depending on future stock price performance.

Heartflow's Business and Market Position

Heartflow Inc. operates in the cardiac imaging and diagnostics sector, providing technology and services for non-invasive assessment of coronary artery disease. The company's core business centers on proprietary software and computational fluid dynamics analysis that generates personalized coronary physiologic assessments. This technology enables clinicians to evaluate blood flow to the heart muscle without requiring invasive catheterization procedures, positioning the company within the broader digital health and precision medicine market segments. The company markets its solutions to hospital systems, imaging centers, and interventional cardiology practices across the United States and internationally.

Heartflow's revenue model derives from licensing its diagnostic platform, providing professional services for image analysis, and generating recurring revenue through software subscriptions and usage-based fees. The company serves a substantial addressable market within cardiovascular diagnostics, where demand for non-invasive assessment tools continues to expand alongside broader healthcare industry adoption of digital health technologies. The insider trading activity disclosed in this report reflects board-level confidence in the company's strategic positioning and operational execution within this specialized medical technology market.

Timing and Filing Documentation

The transaction occurred on July 17, 2026, and the beneficial ownership update was filed with securities regulators on July 20, 2026, within the standard three-business-day reporting window required for Section 16 insiders. Timothy C. Barabe is identified as a director of Heartflow on the disclosure form, confirming his status as a company insider subject to beneficial ownership reporting requirements. The form was filed as a single-person filing rather than a joint or group submission, indicating that Barabe was the sole reporting party for this transaction. The signature line shows authorization through power of attorney by Nga Van, a common administrative arrangement for corporate insiders managing their equity transaction documentation.

The filing includes representations regarding the accuracy and completeness of the beneficial ownership information disclosed. Federal securities law imposes criminal penalties for intentional misstatements or omissions in insider trading reports, creating strong compliance incentives for accuracy in these disclosures. The document confirms that Barabe holds direct beneficial ownership of both the acquired common shares and the granted options, with no indirect ownership structures or third-party holdings reported for these particular securities. This direct ownership arrangement is typical for executive directors and board members managing their personal equity positions in publicly traded companies.

Insider Ownership Implications for Investors

Director stock purchases and option grants represent one category of insider activity that market participants monitor for potential signals about company valuation and leadership confidence. Barabe's acquisition of 5,000 shares at $19 per share, combined with receipt of options at the same strike price, indicates that the director perceives the current share price as attractive for building additional ownership stakes. The size of his total shareholding at 184,521 shares demonstrates sustained commitment to equity ownership in the company. While insider purchases do not guarantee future stock price appreciation, they may reflect board-level assessment of the company's business fundamentals and near-term prospects.

The concurrent grant of stock options creates performance-aligned incentives for Barabe to drive shareholder value over the extended nine-year option term. This combination of common stock ownership and derivative positions is designed to encourage board members to make decisions that benefit long-term shareholders. Investors evaluating Heartflow should consider insider ownership patterns alongside other fundamental metrics, competitive positioning, and industry growth drivers when forming investment decisions. The timing of the transaction in mid-July 2026 and the absence of any restriction notices on the acquired shares suggest routine insider equity transactions rather than opportunistic accumulation ahead of material company announcements.

Regulatory Context and Reporting Obligations

Heartflow qualifies as a publicly traded company with equity securities registered under the Securities Exchange Act of 1934, triggering mandatory beneficial ownership reporting obligations for company directors and certain other insiders. Timothy C. Barabe's reporting obligations stem from his director status at Heartflow, which classifies him as a Section 16 insider under federal securities law. The Form 4 disclosure filed on July 20, 2026, represents the standard mechanism through which insiders report changes in their beneficial ownership positions to the Securities and Exchange Commission and the investing public. These reports become part of the company's public disclosure record accessible through the SEC's EDGAR database.

The regulatory framework requiring Form 4 filings aims to enhance market transparency by ensuring timely public disclosure of insider trading activity. Investors can use these reports to track patterns of insider buying and selling, assess management confidence in company prospects, and identify potential concerns if significant selling occurs. The standardized form structure requires insiders to specify transaction details including security type, quantity, price, and resulting ownership positions, enabling investors to calculate precise holdings and analyze insider activity trends. Barabe's disclosure represents full compliance with these regulatory requirements and provides the investing community with material information about executive equity positioning at Heartflow.

Forward-Looking Considerations for Heartflow Investors

The beneficial ownership update provides a snapshot of insider equity positioning as of July 20, 2026, but does not forecast future company performance, share price movements, or additional insider trading activity. Investors should recognize that this transaction represents historical fact disclosed in compliance with securities law rather than guidance or prediction regarding Heartflow's operational trajectory or market valuation. The company did not disclose any forward-looking financial guidance, revenue projections, earnings estimates, or strategic announcements in connection with this insider trading report. The disclosure is limited to the beneficial ownership transaction and does not include management commentary or analysis of business conditions.

Heartflow operates in the competitive cardiac diagnostics and digital health sectors, where company performance depends on factors including technology adoption by healthcare institutions, reimbursement policies, competitive product development, and regulatory approvals for medical devices and diagnostic platforms. While insider equity positions may indicate board confidence, they represent only one variable among many that influence stock performance and investor returns. Investors analyzing Heartflow should evaluate the company's latest financial results, growth rates, competitive positioning, and market conditions alongside insider trading data when forming investment judgments. The presence of insider stock purchases does not guarantee positive future outcomes and should not serve as the sole basis for investment decisions.

Common Stock and Derivative Securities Summary

The beneficial ownership disclosure shows that Timothy C. Barabe accumulated substantial equity interests in Heartflow through both direct common stock ownership and derivative securities. His 184,521 shares of common stock represent direct beneficial ownership acquired through market purchases and other means over time, including the 5,000-share acquisition disclosed in this July 2026 transaction. The options position of 18,710 shares reflects the grant of options through various dates, with the 5,000-share option grant dated July 17, 2026, representing the most recent allocation. Combined, these positions demonstrate significant financial stake alignment between Barabe and other Heartflow shareholders.

The exercise price of $19 for the newly granted options matches the prevailing market price at which Barabe purchased common shares on the same date, suggesting the option grant reflected competitive market-based compensation rather than heavily discounted pricing. This pricing alignment is typical for equity compensation in publicly traded companies where option strikes are set at fair market value to comply with accounting and regulatory standards. The nine-year expiration window on these options substantially exceeds the typical four-to-ten-year range observed in many technology and healthcare company option plans, potentially reflecting Heartflow's preference for longer-dated incentive structures. The direct ownership form confirms that Barabe has complete beneficial ownership and voting rights with respect to these securities.